Antagonism of DP2 receptor antagonist has been in use for allergic conditions (Kupczyk and Kuna, 2017) and has also been proposed as a therapeutic approach for conditions where PGD2 plays a non-canonical role such as obesity, cancer, viral, and bacterial infections. Here, HPGDS is linked to obesity disorder.